Results 1 to 10 of about 8,944 (181)
Pulmonary hypertension associated with diazoxide: the SUR1 paradox
ERJ Open Research, 2023 The ATP-sensitive potassium channels and their regulatory subunits, sulfonylurea receptor 1 (SUR1/Kir6.2) and SUR2/Kir6.1, contribute to the pathophysiology of pulmonary hypertension (PH).
David Montani +7 more
doaj +2 more sources
Exceptional diazoxide sensitivity in hyperinsulinaemic hypoglycaemia due to a novel HNF4A mutation [PDF]
Endocrinology, Diabetes & Metabolism Case Reports, 2019 Diazoxide is the first-line treatment for patients with hyperinsulinaemic hypoglycaemia (HH). Approximately 50% of patients with HH are diazoxide resistant.
Ved Bhushan Arya +4 more
doaj +2 more sources
Ubiquinol-cytochrome c reductase core protein 1 may be involved in delayed cardioprotection from preconditioning induced by diazoxide. [PDF]
PLoS ONE, 2017 This study aimed to use long-term diazoxide treatment to establish a loss-of-cardioprotection model and then perform proteomics analysis to explore which proteins of mitochondrial inner membrane (MIM) are potentially involved in delayed cardioprotection.
Zonghong Long +7 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022 Background ATP‐sensitive potassium channels are inhibited by ATP and open during metabolic stress, providing endogenous myocardial protection. Pharmacologic opening of ATP potassium channels with diazoxide preserves myocardial function following ...
Ana K. Velez +10 more
doaj +1 more source
A Rare Side Effect of Diazoxide Therapy: Pulmonary Hipertension
Journal of Behçet Uz Children's Hospital, 2020 We present a newborn diagnosed with Beckwith-Wiedemann syndrome and hypoglycemia, and developed pulmonary hypertension due to initiated diazoxide treatment because of these indications.
Alper Hazım Gürsu +4 more
doaj +1 more source
Diazoxide-associated pulmonary hypertension in a patient with noncompaction cardiomyopathy
Pulmonary Circulation, 2021 Development of pulmonary hypertension after initiation of diazoxide for the treatment of neonatal hyperinsulinemic hypoglycemia is a rare, but previously described association.
Rachel T. Sullivan +3 more
doaj +1 more source
Biology, 2022 Obesity is a chronic disease that impairs skeletal muscle function, affects the ability to contract, and promotes the development of fatigue. For this reason, the study of treatments that seek to reduce the harmful effects of obesity on muscle tissue has
Mariana Gómez-Barroso +7 more
doaj +1 more source
Diazoxide use for neonatal hyperinsulinaemic hypoglycaemia in a low-resource setting: A Case Report
Annals of Health Research, 2020 The management of neonatal hyperinsulinaemic hypoglycaemia remains a major challenge in hospitalized newborns globally. Diazoxide is one of the recommended therapeutic options.
Adekoya AO +5 more
doaj +1 more source
Frontiers in Molecular Biosciences, 2023 Background: Diazoxide is a selective mitochondrial-sensitive potassium channel opening agent that has a definite effect on reducing myocardial ischemia/reperfusion injury (MIRI).
Cen Xiang +7 more
doaj +1 more source
K(ATP) channel opener diazoxide prevents neurodegeneration: a new mechanism of action via antioxidative pathway activation. [PDF]
PLoS ONE, 2013 Pharmacological modulation of ATP-sensitive potassium channels has become a promising new therapeutic approach for the treatment of neurodegenerative diseases due to their role in mitochondrial and cellular protection.
Noemí Virgili +6 more
doaj +1 more source